본문 바로가기

Prediction of Metastasis-Free Survival in Patients with Localized Prostate Adenocarcinoma Using Delta Radiomics from Pre-Treatment PSMA-PET/CT Scans and Dosiomics

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
CANCERS18(4) · 2026
피인용
Web of Science 0Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2024 4.4
ISSN
2072-6694

저자

  1. Singh, Apurva제1저자Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
  2. Mendes, William SilvaUniv Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
  3. 오상보Pusan Natl Univ, Sch Med, Dept Internal Med, Div Med Oncol & Hematol,Yangsan Hosp, Yangsan 50612, South Korea
  4. Guler, Ozan CemBaskent Univ, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, Fac Med, TR-01250 Adana, Turkiye
  5. Elmali, AysenurBaskent Univ, Dept Radiat Oncol, Fac Med, TR-06490 Ankara, Turkiye
  6. Demirhan, BirhanBaskent Univ, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, Fac Med, TR-01250 Adana, Turkiye
  7. Sawant, AmitUniv Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
  8. Tran, PhuocUniv Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA
  9. Onal, Cem교신저자Baskent Univ, Adana Dr Turgut Noyan Res & Treatment Ctr, Dept Radiat Oncol, Fac Med, TR-01250 Adana, Turkiye
  10. Ren, Lei교신저자Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA

초록

Purpose: To develop prognostic models integrating delta radiomics from prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) and dosiomics with clinical variables to predict metastasis-free survival (MFS) in patients with localized prostate adenocarcinoma treated with androgen deprivation therapy and external-beam radiotherapy. Materials/Methods: Delta-radiomics analysis included 43 patients. Radiomics features were extracted from the primary tumor on pre- and post-treatment PSMA-PET/CT, and delta features were calculated as relative changes. Eight high-variance features were selected and combined with clinical variables (age, Gleason score, initial PSA, and a binary variable, indicating the occurrence of PSA relapse). Data was split 70:30 with training-set imbalance correction. Predictors that were significant in univariate Cox regression (p < 0.05) were entered into multivariate Cox models, and five-year MFS was classified using a quadratic support vector machine. Dosiomics analysis included 48 patients. Dosiomics features were extracted from the planning target volume receiving 86 Gy and combined with pre-treatment radiomics and clinical variables using the same framework. Results: For delta radiomics, Model 1 (delta radiomics + pre-treatment radiomics + clinical) achieved the best performance (test c-score 0.58; AUC 0.70), exceeding Model 2 (pre-treatment radiomics + clinical; c-score 0.56; AUC 0.65) and Model 3 (clinical only; c-score 0.51; AUC 0.56). For dosiomics, Model 1 showed the highest performance (test c-score 0.56; AUC 0.67) compared with Model 2 (c-score 0.55; AUC 0.62) and Model 3 (c-score 0.50; AUC 0.54). Conclusions: Integrating delta radiomics or dosiomics with pre-treatment imaging and clinical variables improves MFS prediction and supports their role as non-invasive biomarkers for individualized radiotherapy in localized prostate cancer.

키워드

delta radiomicsdosiomicsprognostic modelingprostate cancerPSMA-PET/CT

식별자

Scopus EID
2-s2.0-105031484177
WoS UID
001704208700001